Who we are
ABOUT MEDICINES FOR EUROPE
PURPOSE AND OBJECTIVES
OUR VALUES – OUR 5 PILLARS
STRUCTURE
MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
Vacancies
PRIORITIES
Key topics
ACCESS
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
SUSTAINABILITY
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
EXTERNAL RESOURCES
FACTSHEETS
INFOGRAPHICS
PODCAST
POLICY
REPORTS
VIDEOS
Newsroom
IN THE NEWS
PRESS RELEASES
Contact us
Login
Generic medicines
Home
Medicines for Europe
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Medicines for Europe
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Publications
Filters:
policy
x
By group
By type
External Resources
Factsheets
Infographics
PODCAST
Policy
Reports
Videos
Newsroom
Twitter
Tweets
Videos
Photos
A digital future for value added medicines
24 September 2019
Policy, Report
Read More
Open letter to the Members of the European Parliament on the importance to sustain EU progress in fighting against antimicrobial resistance (AMR)
11 September 2019
Policy
Read More
Medicines for Europe Commentary on the Draft EMA regulatory science strategy 2025
28 June 2019
Policy
Read More
Calls to action to improve access to value added medicines
26 February 2019
Policy, Report
Read More
Case Studies for Value Added Medicines. Unlocking the potential of patient-centric continuous innovation
26 February 2019
Policy, Report
Read More
Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA)
21 June 2018
Policy
Read More
Medicines For Europe Country Specific Market Access Policies
24 May 2018
Policy
Read More
Position paper on Best Procurement Practices
28 April 2018
Policy
Read More
IGBA position on identification of biological, including biosimilar medicines (2018 update of facts & figures)
20 April 2018
Policy
Read More
Life Science Industry Coalition Position paper
14 December 2017
Policy
Read More
Posts navigation
1
…
5
6
7
8
9
…
11
Subscribe to our newsletter
[contact-form-7 id="1638" title="Newsletter subscription"]
Medicines For Europe
Who we are
Vacancies
PRIORITIES
Key topics – COVID-19
Publications
Newsroom
Contact us
SECTOR GROUPS
Generic medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Biosimilar medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Value added medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
Events
Share This
LinkedIn
Share on Mastodon
Enter your Mastodon instance URL (optional)
Share
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
